SRZN
Surrozen IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$306.17M
P/E Ratio
—
EPS
$-36.59
Beta
0.59
52W High
$35.00
52W Low
$7.45
50-Day MA
$28.90
200-Day MA
$20.18
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Surrozen Inc
Surrozen Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutics through its proprietary SIRPa-IgG platform, which focuses on modulating targeted immune responses. The company's diverse pipeline features novel antibody therapeutics aimed primarily at addressing serious oncological and autoimmune conditions, underlining its commitment to tackling significant unmet medical needs. With a solid foundation in research and development and strategic collaborations, Surrozen is well-positioned to deliver transformative therapies, highlighting its potential for substantial growth and impact in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $7.49M |
| Gross Profit (TTM) | $-24.64M |
| EBITDA | $-42.69M |
| Operating Margin | -209.10% |
| Return on Equity | -62.80% |
| Return on Assets | -22.80% |
| Revenue/Share (TTM) | $0.81 |
| Book Value | $-19.21 |
| Price-to-Book | 2.50 |
| Price-to-Sales (TTM) | 40.85 |
| EV/Revenue | 27.54 |
| EV/EBITDA | 0.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 408.60% |
| Shares Outstanding | $11.61M |
| Float | $4.68M |
| % Insiders | 3.18% |
| % Institutions | 101.88% |
Historical Volatility
HV 10-Day
64.34%
HV 20-Day
75.53%
HV 30-Day
79.87%
HV 60-Day
72.28%
HV Rank
62.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($42.50 target)
5
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026